The Rectal Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Rectal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Rectal Cancer. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Rectal Cancer and features dormant and discontinued products.

GlobalData tracks 66 drugs in development for Rectal Cancer by 58 companies/universities/institutes. The top development phase for Rectal Cancer is phase ii with 30 drugs in that stage. The Rectal Cancer pipeline has 65 drugs in development by companies and one by universities/ institutes. Some of the companies in the Rectal Cancer pipeline products market are: Suzhou Ruotai Pharmaceutical Technology, SQZ Biotechnologies and GSK.

The key targets in the Rectal Cancer pipeline products market include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274), and DNA Topoisomerase I (TOP1 or EC 5.99.1.2).

The key mechanisms of action in the Rectal Cancer pipeline product include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist with nine drugs in Phase II. The Rectal Cancer pipeline products include 13 routes of administration with the top ROA being Intravenous and ten key molecule types in the Rectal Cancer pipeline products market including Small Molecule, and Monoclonal Antibody.

Rectal Cancer overview

Rectal cancer affects the lower part of the colon, which connects the large bowel to the anus. The risk factors for developing rectal cancer are increasing age, smoking, family history of colon or rectal cancer, high-fat diet and/or a diet mostly from animal sources, and personal or family history of polyps or colorectal cancer. Rectal cancer commonly spreads to organs such as the liver and the lungs. The common signs and symptoms of rectal cancer include a change in bowel habits, diarrhea, constipation, or feeling that the bowel does not empty completely; blood, either bright red or very dark in the stool; stools that are narrower than usual; general abdominal discomfort such as frequent gas pains, bloating, fullness or cramps; weight loss with no known reason; constant tiredness; and vomiting. Rectal cancer treatment includes surgery, radiation therapy or chemotherapy, or a combination of these approaches.

For a complete picture of Rectal Cancer’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.